

=> s l1

SAMPLE SEARCH INITIATED 12:32:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 66 TO ITERATE

100.0% PROCESSED 66 ITERATIONS
SEARCH TIME: 00.00.01

2 ANSWERS



FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 833 TO 1807
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:32:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 66 TO ITERATE

100.0% PROCESSED 66 ITERATIONS
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 833 TO 1807
PROJECTED ANSWERS: 2 TO 124

L3 2 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 12:32:52 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1258 TO ITERATE

100.0% PROCESSED 1258 ITERATIONS

79 ANSWERS

SEARCH TIME: 00.00.01

L4 79 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 12:33:02 ON 08 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7

FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l4

L5 7 L4

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1135981 CAPLUS

DOCUMENT NUMBER: 146:75148

TITLE: Calpain inhibitors and antioxidants act synergistically to prevent cell necrosis: effects of the novel dual inhibitors (cysteine protease

inhibitor

and antioxidant) BN 82204 and its pro-drug BN 82270 Pignol, Bernadette; Aurin, Serge; Carre, Denis; Marin,

CORPORATE SOURCE: Jean-Gregoire; Chabrier, Pierre-Etienne Department of Neurobiology, Ipsen Research Laboratories, Les Ulis, Fr.

SOURCE: Journal of Neurochemistry (2006), 98(4), 1217-1228 CODEN: JONRA9; ISSN: 0022-3042

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cell death is a common feature observed in neurodegenerative disorders, and is often associated with calpain activation and overprod. of reactive oxygen species (ROS). This study investigated the use of calpain inhibitors and antioxidants in combination to protect cells against necrosis.

Maitotoxin (MTX), which induces a massive influx of calcium, was used to provoke neuronal cell death. This toxin increased, in a concentration-dependent manner, both calpain activity and ROS formation. Calpain inhibitors or antioxidants inhibited MTX-induced necrosis only marginally (below 20%), whereas their association protected against cell death by 40-66% in a synergistic manner. BN 82204, which possesses both calpain-cathepsin L inhibitory and antioxidant properties, and its acetylated pro-drug BN 82270, totally protected cells at 100 μ M. The pro-drug BN 82270, which had better cell penetration, was twice as effective as the active principle BN 82204 in protecting glioma C6 or neuroblastoma SHSY5Y cells against death. These results suggest the potential therapeutic relevance of using a single mol. with multiple activities (cysteine protease inhibitor/antioxidant), and warrant further in vivo investigations in models of neuronal disorders.IT 139007-47-5, BN 82204 742104-24-1, BN 82270
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of calpain inhibitors and antioxidants in combination or single


BN 82204 and its pro-drug BN 82270 with multiple activities to prevent cell necrosis)

RN 139007-47-5 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 742104-24-1 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:583794 CAPLUS

DOCUMENT NUMBER: 145:116788

TITLE: Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression

Fares, Moin U.; Evenson, Amy R.; Wu, Wei; Manconi, Michael; Poylin, Vitaliy; Petkova, Victoria; Pignol, Bernadette; Hasselgren, Per-Olof

CORPORATE SOURCE: Department of Surgery, Harvard Medical School, Boston, MA, USA

SOURCE: American Journal of Physiology (2006), 290(6, Pt. 2), R1589-R1597

CODEN: AJPHAP; ISSN: 0002-9513

PUBLISHER: American Physiological Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Muscle wasting in sepsis is a significant clin. problem because it results

in muscle weakness and fatigue that may delay ambulation and increase the risk for thromboembolic and pulmonary complications. Treatments aimed at preventing or reducing muscle wasting in sepsis, therefore, may have important clin. implications. Recent studies suggest that sepsis-induced muscle proteolysis may be initiated by calpain-dependent release of myofilaments from the sarcomere, followed by ubiquitination and

degradation of the myofilaments by the 26S proteasome. In the present expts., treatment of rats with one of the calpain inhibitors calpeptin or BN82270 inhibited protein breakdown in muscles from rats made septic by cecal ligation and puncture. The inhibition of protein breakdown was not accompanied by reduced expression of the ubiquitin ligases atrogin-1/MAFbx and MuRF1, suggesting that the ubiquitin-proteasome system is regulated independent of the calpain system in septic muscle. When incubated muscles were treated in vitro with calpain inhibitor, protein breakdown rates and calpain activity were reduced, consistent with a direct effect in

skeletal muscle. Addnl. expts. suggested that the effects of BN82270 on muscle protein breakdown may, in part, reflect inhibited cathepsin L activity.

in addition to inhibited calpain activity. When cultured myoblasts were transfected with a plasmid expressing the endogenous calpain inhibitor calpastatin, the increased protein breakdown rates in dexamethasone-treated myoblasts were reduced, supporting a role of calpain activity in atrophying muscle. The present results suggest that treatment with calpain inhibitors may prevent sepsis-induced muscle wasting.

IT 742104-24-1, BN 82270
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1


expression)

RN 742104-24-1 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:128502 CAPLUS

DOCUMENT NUMBER: 144:370406

TITLE: Novel dual inhibitors of calpain and lipid peroxidation with enhanced cellular activity
 AUTHOR(S): Auvin, Serge; Pignol, Bernadette; Navet, Edith; Troadec, Morgane; Carre, Denis; Camara, Jose; Bigg, Dennis; Chabrier, Pierre-E.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Ipsen Research Laboratories, Institut Henri Beaufour, Les Ulis, 91966, Fr.


SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1586-1589
 CODEN: BMCLES; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB A series of dipeptides with dual inhibitory activities on calpain and lipid peroxidation were prepared to target the intracellular calpain. This optimization program focused on the variations of the linker and the N-terminal amino acid of the peptidic core. Two compounds I (R₁ = n-Pr and i-Bu) exhibited potent intracellular calpain inhibition. The polar surface area and the number of rotors appeared to be critical

descriptors to account for the behavior of these hybrid mols. in the cellular calpain assay.

IT 853208-10-3P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)


(preparation by peptide coupling of peptidomimetics as inhibitors of calpain and lipid peroxidation with enhanced cellular activity)

RN 853208-10-3 CAPLUS

CN L-Leucinamide, N-[(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 853208-06-7P 853208-16-9P 853208-22-7P

853208-24-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation by peptide coupling of peptidomimetics as inhibitors of calpain and lipid peroxidation with enhanced cellular activity)

RN 853208-06-7 CAPLUS

CN L-Leucinamide, N-[(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-16-9 CAPLUS

CN L-Leucinamide,

N-[(10H-phenothiazin-2-ylacetyl)-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-22-7 CAPLUS

CN L-Leucinamide,

N-[1-oxo-3-[(10H-phenothiazin-2-yl)propyl]-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 853208-13-6P 853208-19-2P 853208-23-8P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation by peptide coupling of peptidomimetics as inhibitors of calpain and lipid peroxidation with enhanced cellular activity)

RN 853208-13-6 CAPLUS

CN L-Leucinamide, N-[(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-N-[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-19-2 CAPLUS

CN L-Leucinamide,

N-[(10H-phenothiazin-2-ylacetyl)-L-leucyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-23-8 CAPLUS

CN L-Leucinamide,

N-[1-oxo-3-[(10H-phenothiazin-2-yl)propyl]-L-leucyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 853208-24-9 CAPLUS

CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 853208-43-2P 853208-44-3P 853208-45-4P

853208-46-5P 853208-49-8P 853208-50-1P

853208-51-2P 853208-52-3P 853208-53-4P

853208-54-5P 853208-55-6P 853208-57-8P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of peptidomimetics as inhibitors of intracellular calpain and lipid peroxidation, and structure-activity relationship)

RN 853208-43-2 CAPLUS

CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-leucyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-44-3 CAPLUS

CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-45-4 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-alanyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-46-5 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-49-8 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-D-valyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-54-5 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-threonyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-55-6 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-2-phenylglycyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-57-8 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-alanyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 853208-50-1 CAPLUS
CN L-Leucinamide, 3-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-51-2 CAPLUS
CN Pentenamide, 4-methyl-2-[(2S)-1-oxo-2-[(10H-phenothiazin-2-yloxy)acetyl]amino]butyl]amino]-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-52-3 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-norvalyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-53-4 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-seryl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1075636 CAPLUS
 DOCUMENT NUMBER: 143:339689
 TITLE: Use of a phenothiazine derivative for preventing and/or treating hearing loss
 INVENTOR(S): Pignol, Bernadette; Puel, Jean-Luc; Auvin, Serge; Chabrier de Lasseuniere, Pierre-Stienne; Wang, Jing
 PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.C.R.A.S., Fr.
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092345	A1	20051006	WO 2005-FR713	20050325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2867979	A1	20050930	FR 2004-3203	20040329
FR 2867979	B1	20060630		
CA 2560988	A1	20051006	CA 2005-2560988	20050325
EP 1732567	A1	20061220	EP 2005-744629	20050325
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.: FR 2004-3203 A 20040329				
FR 2004-6404 A 20040614				
WO 2005-FR713 W 20050325				

OTHER SOURCE(S): MARPAT 143:339689
 GI

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention discloses the use of a phenothiazine derivative I (R = H, alkyl,

aralkyl, etc.) for preparing a medicine for preventing and/or treating hearing loss.

IT 339007-47-5 339007-47-5D, derive. 742104-24-1

866006-13-5 866006-13-5D, derive. 866006-14-6

866006-14-6D, derive. 866006-15-7 866006-15-7D

, derive. 866006-16-8 866006-16-8D, derive.

866006-17-9 866006-17-9D, derive.


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phenothiazine derive. for prevention and/or treatment of hearing loss)

RN 339007-47-5 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 339007-47-5 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 742104-24-1 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide,
 N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866006-13-5 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide,
 N-[(1S)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-13-5 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide,
 N-[(1S)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866006-14-6 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide,
 N-[(1S)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 866006-14-6 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide,
 N-[(1S)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866006-15-7 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-15-7 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866006-16-8 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide,
 N-[(1R)-3-methyl-1-[[[(2S,3S)-tetrahydro-


L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866006-16-8 CAPLUS
CN 10H-Phenothiazine-2-carboxamide,
N-[(1R)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-17-9 CAPLUS
CN 10H-Phenothiazine-2-carboxamide,
N-[(1R)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-17-9 CAPLUS
CN 10H-Phenothiazine-2-carboxamide,
N-[(1R)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:492131 CAPLUS
DOCUMENT NUMBER: 143:44075
TITLE: Preparation of peptidyl 3-aminotetrahydro-2-furanol derivatives for use as drugs
INVENTOR(S): Auvin, Serge; Chabrier De Lasseau, Pierre Etienne
PATENT ASSIGNEE(S): Societe De Conseils de Recherches et d'Applications Scientifiques SCRAS, Fr.
SOURCE: Fr. Demande, 53 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2863268	A1	20050610	FR 2003-14368	20031209
FR 2863268	B1	20060224		
CA 2548448	A1	20050623	CA 2004-2548448	20041208
WO 2005056551	A2	20050623	WO 2004-FR3147	20041208
WO 2005056551	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1701974	A2	20060920	EP 2004-816363	20041208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 2006166893	A1	20060727	US 2005-532731	20050426
US 2005222045	A1	20051006	US 2005-115480	20050427
PRIORITY APPLN. INFO.: FR 2003-14368 A 20031209				
WO 2004-FR3147 W 20041208				


OTHER SOURCE(S): MARPAT 143:44075
GI



AB The invention relates to peptide deriva. I [A is (un)substituted carbazoyl, dibenzob[flaxepinyl or 10,11-dihydro deriva., phenoxazinyl, phenothiazinyl or phenazinyl; X is CO, Y-CO, O-Y-CO or NRI-Y-CO; Y is

Habte

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

FORMAT


RECORD. ALL CITATIONS AVAILABLE IN THE RE

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

alkylene or haloalkylene; R, R1 are independently H, alkyl or acyl; AA is a natural amino acid or deriv.; n is 2,3] or their salts which inhibit calpains and lipid peroxidn. and can be used to treat inflammatory, immunol., cardiovascular and other diseases. Thus,
N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-L-leucyl-N-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide was prepd. by a multistep procedure involving reactions of Chz-L-Leucine (Chz = benzylloxycarbonyl), (S)-2-amino-4-butyrolactone hydrobromide, and 2-acetylphenothiazine and treatment with 2N HCl. The product showed IC50 < 5 µM for inhibition of human calpain I.
IT 853208-03-4P 853208-04-5P 853208-05-6P
853208-06-7P 853208-07-8P 853208-08-9P
853208-10-3P 853208-11-4P 853208-16-9P
853208-17-0P 853208-18-1P 853208-62-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptidyl aminotetrahydrofuranol deriva. for use as drugs)


RN 853208-03-4 CAPLUS
CN L-Leucinamide,
N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-04-5 CAPLUS
CN L-Leucinamide,
N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853208-05-6 CAPLUS
CN L-Leucinamide,
N-(10H-phenothiazin-2-ylcarbonyl)glycyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-06-7 CAPLUS
CN L-Leucinamide, N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-07-8 CAPLUS
CN L-Leucinamide, N2-(10H-phenothiazin-2-ylcarbonyl)-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853208-08-9 CAPLUS
CN L-Leucinamide, 1-(10H-phenothiazin-2-ylcarbonyl)-L-prolyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-17-0 CAPLUS
CN L-Leucinamide, O-(1,1-dimethylethyl)-N-(10H-phenothiazin-2-ylacetyl)-L-seryl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-18-1 CAPLUS
CN L-Alaninamide, N-(10H-phenothiazin-2-ylacetyl)-L-alanyl-3-cyclohexyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-62-5 CAPLUS
CN L-Leucinamide, N-(10H-phenothiazin-2-ylacetyl)-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Habte

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-10-3 CAPLUS
CN L-Leucinamide, N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-11-4 CAPLUS
CN L-Leucinamide, N2-(10H-phenothiazin-2-ylcarbonyl)-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-16-9 CAPLUS
CN L-Leucinamide, N-(10H-phenothiazin-2-ylacetyl)-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 853208-09-0P 853208-12-5P 853208-13-6P
853208-15-8P 853208-19-2P 853208-20-5P
853208-21-6P 853208-22-7P 853208-23-8P
853208-24-9P 853208-25-0P 853208-26-1P
853208-27-2P 853208-28-3P 853208-29-4P
853208-30-7P 853208-31-8P 853208-32-9P
853208-33-0P 853208-34-1P 853208-35-2P
853208-36-3P 853208-37-4P 853208-38-5P
853208-39-6P 853208-40-9P 853208-41-0P
853208-42-1P 853208-43-2P 853208-44-3P
853208-45-4P 853208-46-5P 853208-47-6P
853208-48-7P 853208-49-8P 853208-50-1P
853208-51-2P 853208-52-3P 853208-53-4P
853208-54-5P 853208-55-6P 853208-56-7P
853208-57-8P 853208-58-9P 853208-59-0P
853208-60-1P 853208-61-4P 853208-63-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptidyl aminotetrahydrofuranol derivs. for use as drugs)


RN 853208-09-0 CAPLUS
CN L-Leucinamide, N-(10H-phenothiazin-2-ylcarbonyl)glycyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-12-5 CAPLUS
CN L-Leucinamide, N-(10H-phenothiazin-2-ylcarbonyl)-L-prolyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-13-6 CAPLUS
CN L-Leucinamide, N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-N-[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]- (9CI) (CA INDEX NAME)

02/08/2007

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 853208-15-8 CAPLUS
 CN L-Leucinamide, N2-(10H-phenothiazin-2-ylcarbonyl)-L-lysyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 853208-14-7
 CMP C29 H39 N5 O5 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMP C2 H F3 O2



RN 853208-19-2 CAPLUS
 CN L-Leucinamide, N-(10H-phenothiazin-2-ylacetyl)-L-leucyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-23-8 CAPLUS
 CN L-Leucinamide, N-(1-oxo-3-(10H-phenothiazin-2-yl)propyl)-L-leucyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-24-9 CAPLUS
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-25-0 CAPLUS
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853208-26-1 CAPLUS
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-alanyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Habt

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-20-5 CAPLUS
 CN L-Leucinamide, O-(1,1-dimethylethyl)-N-(10H-phenothiazin-2-ylacetyl)-L-seryl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-21-6 CAPLUS
 CN L-Alaninamide, N-(10H-phenothiazin-2-ylacetyl)-L-alanyl-3-cyclohexyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-22-7 CAPLUS
 CN L-Leucinamide, N-(1-oxo-3-(10H-phenothiazin-2-yl)propyl)-L-leucyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 853208-27-2 CAPLUS
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-28-3 CAPLUS
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-β-alanyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-29-4 CAPLUS
 CN L-Leucinamide, N-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853208-30-7 CAPLUS


L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-D-valyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-31-8 CAPLUS
 CN L-Leucinamide, 3-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-32-9 CAPLUS
 CN Pentanamide, 4-methyl-2-[[[(2S)-1-oxo-2-[[[(10H-phenothiazin-2-yloxy)acetyl]amino]butyl]amino]-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]-], (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853208-33-0 CAPLUS
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-norvalyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-37-4 CAPLUS
 CN Pentanamide, 4-methyl-2-[[[(2S)-1-oxo-2-[[[(10H-phenothiazin-2-yloxy)acetyl]amino]-3-butenyl]amino]-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]-], (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-38-5 CAPLUS
 CN L-Leucinamide, 2-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]alanyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-39-6 CAPLUS
 CN L-Valinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853208-40-9 CAPLUS


Habte

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-34-1 CAPLUS
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-seryl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-35-2 CAPLUS
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-threonyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-36-3 CAPLUS
 CN L-Leucinamide, (2S)-N-[(10H-phenothiazin-2-yloxy)acetyl]-2-phenylglycyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN L-Alaninamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-3-cyclohexyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-41-0 CAPLUS
 CN L-Phenylalaninamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-42-1 CAPLUS
 CN Glycinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N2-(2-methylpropyl)-N-[(3S)-tetrahydro-2-methoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-43-2 CAPLUS
 CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-leucyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-44-3 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-45-4 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-alanyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-46-5 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-51-2 CAPLUS
CN Pentanamide, 4-methyl-2-[[[(2S)-1-oxo-2-[[[(10H-phenothiazin-2-yloxy)acetyl]amino]butyl]amino]-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]-], (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-52-3 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-norvalyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-53-4 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-seryl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-54-5 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-L-threonyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Habte

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 853208-47-6 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-β-alanyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-48-7 CAPLUS
CN L-Leucinamide, N-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-49-8 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]-D-valyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-50-1 CAPLUS
CN L-Leucinamide, 3-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 853208-55-6 CAPLUS
CN L-Leucinamide, (2S)-N-[(10H-phenothiazin-2-yloxy)acetyl]-2-phenylglycyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-56-7 CAPLUS
CN Pentanamide, 4-methyl-2-[[[(2S)-1-oxo-2-[[[(10H-phenothiazin-2-yloxy)acetyl]amino]-3-butenyl]amino]-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]-], (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853208-57-8 CAPLUS
CN L-Leucinamide, 2-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]alanyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-58-9 CAPLUS
CN L-Valinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-59-0 CAPLUS
CN L-Alaninamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-3-cyclohexyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853208-60-3 CAPLUS
CN L-Phenylalaninamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:498592 CAPLUS
DOCUMENT NUMBER: 141:207514
TITLE: Novel dual inhibitors of calpain and lipid peroxidation
AUTHOR(S): Auvin, Serge; Pignol, Bernadette; Navet, Edith; Pons, Dominique; Marin, Jean-G.; Bigg, Dennis; Chabrier, Pierre-E.
CORPORATE SOURCE: Department of Medicinal Chemistry, Ipsen Research Laboratories, Institut Henri Beaufour, Les Ulis, 91966, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3825-3828
CODEN: BMCLES; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:207514
GI



AB A series of mols. 1 (R1 = phenothiazin-1-yl, phenothiazin-2-yl, 1-benzyl-5-indolinylamino, etc., R2 = H; R1 = phenothiazin-2-yl, R2 = MeCO) with dual inhibitory activities on calpain and lipid peroxidn. were synthesized. These hybrid compds. were built on the calpain pharmacophore

2-hydroxytetrahydrofuran linked to a set of antioxidants via a L-leucine linker. 1 (R1 = phenothiazin-2-yl, R2 = MeCO), the most potent in cellular calpain and lipid peroxidn. inhibitions, provided effective protection against glial cell death induced by maitotoxin.


IT 339007-47-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (peptidyl) (hydroxy) tetrahydrofurans as dual inhibitors of

calpain and lipid peroxidn.)

RN 339007-47-5 CAPLUS


CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Habte

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 853208-61-4 CAPLUS
CN Glycinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N2-(2-methylpropyl)-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853208-63-6 CAPLUS
CN L-Leucinamide, N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 339007-51-1P 742104-24-1P, BN 82270
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (peptidyl) (hydroxy) tetrahydrofurans as dual inhibitors of calpain and lipid peroxidn.)

RN 339007-51-1 CAPLUS


CN 10H-Phenothiazine-1-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 742104-24-1 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:338525 CAPLUS
 DOCUMENT NUMBER: 134:353248
 TITLE: Novel heterocyclic compounds and their use as medicines
 INVENTOR(S): Auvin, Serge; Chabrier De Lessauniere, Pierre-Etienne
 PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032654	A2	20010510	WO 2000-FR3067	20001103
WO 2001032654	A3	20010927		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, RE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2800737	A1	20010511	FR 1999-13858	19991105
FR 2800737	B1	20060630		
FR 2809398	A1	20011130	FR 2000-6535	20000523
FR 2809398	B3	20020726		
CA 2389685	A1	20010510	CA 2000-2389685	20001103
BR 2000015315	A	20020625	BR 2000-15315	20001103
EP 1233962	A2	20020828	EP 2000-974646	20001103
EP 1233962	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200203183	A2	20030228	HU 2002-3183	20001103
JP 2003513092	T	20030408	JP 2001-534805	20001103
NZ 518420	A	20040227	NZ 2000-518420	20001103
AU 781551	B2	20050526	AU 2001-12871	20001103
RU 2460009	C2	20050910	RU 2002-114696	20001103
AT 318809	T	20060315	AT 2000-974646	20001103
EP 1661564	A1	20060531	EP 2005-77194	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
PT 1233962	T	20060731	PT 2000-974646	20001103
ES 2259617	T3	20061016	ES 2000-974646	20001103
US 6747024	B1	20040608	US 2002-111994	20020430
NO 2002002088	A	20020502	NO 2002-2088	20020502
IN 2002MH00504	A	20050304	IN 2002-MH0504	20020513
US 2004180936	A1	20040916	US 2004-803387	20040316
AU 2005203713	A1	20050915	AU 2005-203713	20050818
PRIORITY APPLN. INFO.:			FR 1999-13858	A 19991105

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 339007-49-7 CAPLUS
 CN 4-Thiazolecarboxamide, 2-(10H-phenothiazine-2-yl)-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 339007-50-0 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide, N-[4-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-51-1 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 339007-52-2 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, (3S)-tetrahydro-3-[[[(2S)-4-methyl-1-oxo-2-[[10H-phenothiazin-2-ylcarbonyl]amino]pentyl]amino]-2-furanyl ester (9CI) (CA INDEX NAME)

Hasbe

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 FR 2000-6535 A 20000523
 EP 2000-974646 A3 20001103
 WO 2000-FR3067 W 20001103
 US 2002-111994 A3 20020430


OTHER SOURCE(S): MARPAT 134:353248
 AB Novel heterocyclic deriva. which have calpain inhibiting and/or reactive oxygen species trapping activity (no data) are reported. Thus, (R)-Troxol was treated with (S)-2-aminobutyrolactone hydrochloride, followed by DIBAL reduction to give (2R)-6-hydroxy-N-[(3S)-2-hydroxytetrahydrofuran-3-yl]-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-carboxamide.
 IT 339007-47-5P 339007-48-6P 339007-49-7P 339007-50-0P 339007-51-1P 339007-52-2P 339007-53-3P 339007-54-4P 339007-55-5P 339007-56-6P 339007-57-7P 339007-76-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel heterocyclic compds. as calpain inhibitors and trapping agents for reactive oxygen species)
 RN 339007-47-5 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 339007-48-6 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2S,3S)-2-(acetoxyl)oxy]tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 339007-53-3 CAPLUS
 CN Butanoic acid, 3,3-dimethyl-, (3S)-tetrahydro-3-[[[(2S)-4-methyl-1-oxo-2-[[10H-phenothiazin-2-ylcarbonyl]amino]pentyl]amino]-2-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-54-4 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(benzoyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 339007-55-5 CAPLUS
 CN Benzenecetic acid, (3S)-tetrahydro-3-[[[(2S)-4-methyl-1-oxo-2-[[10H-phenothiazin-2-ylcarbonyl]amino]pentyl]amino]-2-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


02/08/2007

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 339007-56-6 CAPLUS
 CN L-Phenylalanine, N,N-dimethyl-,
 (3S)-tetrahydro-3-[[[(2S)-4-methyl-1-oxo-2-
 [[10H-phenothiazin-2-ylcarbonyl]amino]pentyl]amino]-2-furanyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-57-7 CAPLUS
 CN 4-Morpholinecarboxylic acid, (3S)-tetrahydro-3-[[[(2S)-4-methyl-1-oxo-2-
 [[10H-phenothiazin-2-ylcarbonyl]amino]pentyl]amino]-2-furanyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 339007-76-0 CAPLUS
 CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2R,3S)-2-
 (acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (9CI)
 (CA INDEX NAME)

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
INDEX NAME

Absolute stereochemistry.



(2)

chain nodes :

19 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

14-19 15-20

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-13 10-11 11-12 12-13
14-15 14-18 15-16 16-17 17-18

exact/norm bonds :

5-7 6-9 7-8 14-19 15-20

exact bonds :

14-15 14-18 15-16 16-17 17-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-10 9-13 10-11 11-12 12-13

isolated ring systems :

containing 14 :

Match level :



1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:37:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 66 TO ITERATE

100.0% PROCESSED 66 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 833 TO 1807
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 12:37:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1258 TO ITERATE

100.0% PROCESSED 1258 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L3 0 SEA SSS FUL L1

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	172.10	172.31

STN INTERNATIONAL LOGOFF AT 12:37:39 ON 08 FEB 2007